Drug · CHEMBL64
ISONIAZID
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ISONIAZID. Drugs and targets, record CHEMBL64. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL64
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
- Dow-isoniazid, Hyzyd, Inh, Isoniazid component of rifamate, Isoniazid component of rifater, Laniazid, Nicotibine, Nydrazid, Rimifon, Stanozide
- ChEMBL
- Other names
Armazid, Armazide, Atcotibine, Cedin, Cotinazin, Dianicotyl, Eralon, Ertuban, Hidrasonil, Hydrazid, Ipcazide, Iscotin, Isidrina, Isobicina, Isoniazida, Isoniazide, Isoniazidum, Isonicotan, Mybasan, NSC-9659, Neumandin, Teebaconin, Tisiodrazida
- ChEMBL
- Open Targets' highest stage
- Approval, for 4 of its 23 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases23
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 23Source Open Targets
See all 23 diseasesTrials194
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 11 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00023452 | Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection | Phase 3 | 8,053 | 2012-09-27 | isoniazid | Its name | ClinicalTrials.gov |
| NCT01404312 | Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB) | Phase 3 | 3,000 | 2018-12-06 | isoniazid | Its name | ClinicalTrials.gov |
| NCT00864383 | Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis | Phase 3 | 1,931 | 2015-05-25 | isoniazid | Its name | ClinicalTrials.gov |
| NCT00080119 | Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV | Phase 2/3 | 1,354 | 2010-10-19 | isoniazid | Its name | ClinicalTrials.gov |
| NCT01582711 | Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT | Phase 3 | 1,002 | 2025-03-13 | isoniazid | Its name | ClinicalTrials.gov |
| NCT01494038 | Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women | Phase 4 | 956 | 2018-11-20 | isoniazid | Its name | ClinicalTrials.gov |
| NCT02821832 | Using Biomarkers to Predict TB Treatment Duration | Phase 2 | 946 | 2022-12-20 | isoniazid | Its name | ClinicalTrials.gov |
| NCT01380080 | REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment | Phase 4 | 851 | 2016-02-23 | isoniazid, rifampin/isoniazid fixed-dose combination | Its name | ClinicalTrials.gov |
| NCT02409290 | The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB | Phase 3 | 588 | 2023-09-28 | isoniazid | Its name | ClinicalTrials.gov |
| NCT04703075 | Ultra Curto (Ultra Short) TB Prevention Therapy | Phase 4 | 531 | 2025-06-19 | isoniazid | Its name | ClinicalTrials.gov |
1 to 10 of 194
See all 194 trialsComparisons in its trials59
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| 9INH vs 3RPT/INH: serious adverse events | 102 of 3,759 | 60 of 4,040 | 7,799 | NCT00023452 | Trial comparisons |
| RPT Plus INH Regimen (Arm A) vs INH Regimen (Arm B): deaths from any cause | 21 of 1,496 | 27 of 1,504 | 3,000 | NCT01404312 | Trial comparisons |
| RPT Plus INH Regimen (Arm A) vs INH Regimen (Arm B): serious adverse events | 40 of 1,496 | 68 of 1,504 | 3,000 | NCT01404312 | Trial comparisons |
| Arm A (Immediate INH Treatment) vs Arm B (Deferred INH Treatment): Number of Mothers With a Fetal Death | 17 of 459 | 9 of 466 | 925 | NCT01494038 | Trial comparisons |
| Arm A (Immediate INH Treatment) vs Arm B (Deferred INH Treatment): Number of Infants Hospitalized | 73 of 445 | 75 of 464 | 909 | NCT01494038 | Trial comparisons |
| Arm A (Immediate INH Treatment) vs Arm B (Deferred INH Treatment): Number of Infants With Grade 3 or Higher Clinical or Laboratory AE Related to Treatment | 5 of 445 | 6 of 464 | 909 | NCT01494038 | Trial comparisons |
| Arm A (Immediate INH Treatment) vs Arm B (Deferred INH Treatment): Number of Infants With Grade 3 or Higher Clinical or Laboratory AE | 193 of 445 | 196 of 464 | 909 | NCT01494038 | Trial comparisons |
| Arm A (Immediate INH Treatment) vs Arm B (Deferred INH Treatment): Number of Mothers With an Infant Born Prematurely | 48 of 442 | 40 of 458 | 900 | NCT01494038 | Trial comparisons |
| Arm A: Empiric vs Arm B: IPT: deaths from any cause | 36 of 424 | 44 of 426 | 850 | NCT01380080 | Trial comparisons |
| Arm A: Empiric vs Arm B: IPT: serious adverse events | 85 of 424 | 94 of 426 | 850 | NCT01380080 | Trial comparisons |
1 to 10 of 59
See all 59 comparisons in its trialsPapers from its trials218
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials2
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Category Fluency | 1 | 0 | ConductCognition |
| Verbal Learning | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL64
GET https://conductscience.org/api/drugs/v1/CHEMBL64/diseases?page=2